Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an announcement.
Perseus Proteomics, Inc. has entered a joint research agreement with Eurus Therapeutics Inc. to combine their technologies for developing new therapeutic agents. This collaboration aims to explore new antibody candidates and assess their potential as therapeutic tools, though it is expected to have minimal immediate impact on Perseus’s performance.
More about Perseus Proteomics, Inc.
Perseus Proteomics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic agents using its proprietary antibody library. The company collaborates with other biotech firms to leverage its technology for innovative medical solutions.
Average Trading Volume: 213,747
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.6B
Learn more about 4882 stock on TipRanks’ Stock Analysis page.